Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 16Other hematologic neoplasm 15Lymphoid 11Sarcoma 2Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 725Neoplasms, Plasma Cell 135Lymphoma, Non-Hodgkin 118Lymphoma 111Recurrence 103Leukemia, Lymphocytic, Chronic, B-Cell 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Leukemia, Myeloid, Acute 92Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 83Leukemia 75Lymphoma, Mantle-Cell 71Myelodysplastic Syndromes 70Lymphoma, Follicular 69Burkitt Lymphoma 60Lymphoma, B-Cell, Marginal Zone 59Neoplasms 54Lymphoma, Large-Cell, Immunoblastic 54Waldenstrom Macroglobulinemia 42Myeloproliferative Disorders 39Leukemia, Myelomonocytic, Chronic 39Leukemia, Myeloid, Chronic-Phase 39Primary Myelofibrosis 38Immunoglobulin Light-chain Amyloidosis 38Hematologic Neoplasms 38Lymphoma, T-Cell, Cutaneous 36Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large-Cell, Anaplastic 34Leukemia, Myeloid, Accelerated Phase 34Blast Crisis 33

Interventions

fludarabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blastic Plasmacytoid Dendritic Cell Neoplasm × Plasma cell × Clear all
NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Senti Biosciences

Phase 1 Active not recruiting
21 enrolled
MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡